Effects of Lanthanum Carbonate on Whole-Body Phosphorus and Calcium Balance in Adults With Chronic Kidney Disease and Normophosphatemia Authors: Anna Jovanovich, Michel Chonchol, Taylor Struemph, Tyson J. Marden, Ester Oh, Zhiying You, Moshe Levi, Gregory G. Schwartz, Kristen L. Nowak, Kathleen M. Hill Gallant Published: 2026 ABSTRACT Rationale & ObjectiveGreater serum phosphorus is associated with cardiovascular disease in those with chronic kidney disease (CKD). However, the utility of phosphorus lowering in nondialysis-requiring CKD is not clear. The effects of noncalcium-based phosphate binders on phosphorus and calcium balance in nondialysis-requiring CKD are unknown. Our objective was to determine phosphorus and calcium balance in normophosphatemic adults with CKD 3b-4 after 12 weeks of treatment with lanthanum carbonate or placebo.Study DesignProspective, randomized, controlled, double-blind clinical trial.Setting & ParticipantsA subset of 15 adults with CKD 3b-4 and serum phosphorus levels within normal limits who participated in a 12-week parallel-arm, randomized controlled trial of lanthanum carbonate compared with placebo on vascular function participated in this study extension.InterventionAt the end of 12 weeks, the subset of participants consumed a controlled diet (1,000 mg/day phosphorus and 800 mg/day calcium) for 9 days and continued their randomly assigned study drug (N = 7 lanthanum carbonate, N = 8 placebo). Fasting morning blood samples and all stool and urine were collected during a 48-hour inpatient clinical research center stay at the end of the 9-day controlled diet period.OutcomesPhosphorus and calcium balance (mg/d) were determined by values averaged over the 48 hours inpatient clinical research center admission.ResultsMean age was 65 ± 8 (SD) years, and mean estimated glomerular filtration rate was 38 ± 14 (SD) mL/min/1.73m2. Whole-body phosphorus balance was lower with lanthanum carbonate compared with placebo (–131 ± 163 [SEM] vs 320 ± 141 mg/d, P = 0.05), as was calcium balance (–46 ± 115 [SEM] vs 410 ± 100 mg/d, P = 0.01), corresponding to lower intestinal absorption supported by the fecal calcium and phosphorus and net absorption results. Neither 24-hour urine calcium nor phosphorus output was significantly different between lanthanum carbonate and placebo, but 24-hour urine phosphorus output differed between lanthanum carbonate and placebo but was not significant (388 ± 60 vs 513 ± 56 mg/d, p=0.15).LimitationsSmall sample size.ConclusionsTwelve weeks of treatment with the noncalcium-based phosphate binder, lanthanum carbonate, may reduce whole-body phosphorus balance as well as calcium balance among adults with stage 3b-4 CKD and normophosphatemia. Whether reduced phosphorus balance or calcium balance with lanthanum carbonate is associated with beneficial clinical outcomes in CKD warrants further investigation. Chronic kidney disease mineral bone disorder (CKD-MBD) is common in chronic kidney disease (CKD), and the biochemical alterations of CKD-MBD include elevated serum phosphorus, parathyroid hormone (PTH), and fibroblast growth factor-23 (FGF23) levels and decreased 1,25-dihydroxyvitamin D (1,25D) and serum calcium levels.1 Notably, abnormal mineral metabolism is observed early in kidney disease progression with abnormalities in PTH, FGF23, and 1,25D, but these hormones act to maintain serum phosphorus or calcium levels in their normal ranges until late stage of the disease.1,2 The changes related to phosphorus homeostasis are considered key factors in the development of vascular and soft tissue calcification in CKD-MBD, even while serum phosphorus levels remain normal. Higher serum phosphorus levels within the reference range are associated with greater mortality in adults with nondialysis-requiring CKD, as well as the general community population, and in those with type 2 diabetes.3, 4, 5 Despite this, in adults with nondialysis-requiring CKD and normophosphatemia, phosphate binders have not improved vascular function, an independent predictor of cardiovascular disease (CVD).6, 7, 8, 9, 10 Hence, the association of abnormalities of phosphorus homeostasis with adverse clinical outcomes in CKD has generated interest in developing therapeutic strategies to target mineral metabolism early in the course of CKD. Despite decreases in kidney function, serum phosphorus is typically maintained in the normal range in early to moderate nondialysis-requiring CKD.3,11 However, serum phosphorus levels reflect only a small fraction of total body phosphorus that is hormonally regulated. Much less is known about whole-body phosphorus balance in nondialysis-requiring CKD, as it cannot be inferred from serum or urine phosphorus measures alone.11 This has been demonstrated with balance studies in adults with CKD, in whom neither calcium nor phosphorus whole-body balance relates to serum calcium or phosphorus levels, which were within the reference ranges.12,13 Previous calcium balance studies performed in adults with CKD stages 3-4, showed that whole-body phosphorus balance remained neutral despite administration of 1,500 mg of calcium as a phosphate binder, which did, however, increase calcium absorption and whole-body calcium balance.13,14 However, there are no studies evaluating the effect of noncalcium-based phosphate binders on phosphorus balance in adults with CKD, which limits the identification of the best approach to treatment of CKD-MBD abnormalities that occur during kidney function decline. Whether long-term treatment with noncalcium-based phosphate binders induces a lower or negative phosphorus balance in CKD patients is uncertain. The purpose of this study was to determine the effect of the noncalcium-based phosphate binder lanthanum carbonate on phosphorus and calcium whole-body balance in adults with stage 3b and 4 CKD while on a controlled diet for 9 days after 12 weeks of treatment with lanthanum carbonate or placebo. Materials and Methods Patients and study design Participants comprised a subgroup of a larger randomized controlled trial of 12 weeks duration that examined the effects of lanthanum carbonate vs placebo on vascular function.6 In brief, the study included men and postmenopausal women ages 40-79 years with CKD stages 3b and 4 (estimated glomerular filtration rate (eGFR) 15-45 mL/min/1.73 m2), serum phosphorus levels 2.8-5.5 mg/dL, albumin >3.0 g/dL, body mass index (BMI) <40 kg/m2, and able to provide informed consent.6 As an extension of this 12-week randomized controlled trial, a subset of 15 participants selected randomly from both the lanthanum carbonate (N = 7) and placebo (N = 8) groups were enrolled in this study extension and asked to complete an additional 9 days consuming a controlled diet and completing a 48-hour phosphorus balance study (Fig 1). Of note, participants were kept on their original randomized assignment of lanthanum carbonate or placebo, and there was no crossover among treatment groups (ie, there was no randomization or reassignment at the beginning of this 9-day controlled diet study or change in lanthanum carbonate dose during the 9-day controlled diet study period). None of the participants were receiving any bone-modifying medications, and all participants were instructed to discontinue calcium supplements and any vitamin and mineral supplements or antacids containing calcium at least 1 month before entry into the main 12-week study.Figure 1Study design. Abbreviation: CTRC, Clinical and Translational Research Center. Study design. Abbreviation: CTRC, Clinical and Translational Research Center. Study oversight The Colorado Multiple Institutional Review Board (COMIRB) protocol number 13-0328 approved the study. All participants provided written informed consent. The study was registered at clinicaltrials.gov (NCT 02209636). Controlled diet At the end of the main 12-week randomized controlled trial, this subset of participants continued taking their current dose of lanthanum carbonate (N = 7) or placebo (N = 8). As in the main study, participants received lanthanum carbonate tablets (500 mg/tablet) or a matching placebo, and the number of daily lanthanum or placebo tablets was determined from a sliding scale according to baseline serum phosphorus levels in the main study (Table S1). Participants in this study were given a controlled diet designed to contain 1,000 ± 50 mg/day phosphorus and 800 ± 50 mg/day calcium for 7 days as an outpatient equilibration period before a 48-hour inpatient stay for balance measurements. The study diet was designed by a registered dietitian (TJM) using ProNutra dietary analysis software (Viocare, Inc., Princeton, NJ).15, 16, 17, 18, 19 All outpatient and inpatient meals were prepared in the metabolic kitchen at the Clinical Trials Research Center (CTRC) at the University of Colorado Anschutz Medical Campus. Of note, ingredients were precisely measured to the 0.1 g. Daily diet composites were prepared in the same fashion and frozen until later analysis of mineral content. Energy content of the diets was designed to match each participant’s estimated needs.17 All meals and snacks were prepared in the CTRC dietary facilities and provided to the participants as pack-outs to consume at home. Participants were instructed to eat only the study food and beverages provided, but could drink plain water ad lib. They were instructed to fully consume all the study meals and snacks, and to keep a diet and pill checklist and return any unconsumed food and pills. Dietary adherence was assessed by meal checklists, and leftover food was recorded, weighed, frozen, and stored for later analysis of unconsumed mineral amounts. Pill adherence was assessed by pill count. Following the 7-day outpatient controlled-diet period, participants were admitted to CTRC for a 48-hour balance study. The controlled study diet and lanthanum carbonate or placebo were continued during the CTRC admission. During the 48-hour CTRC inpatient stay, each participant had two timed 24-hour urine collections for calcium, phosphorus, and creatinine measurements, and fasting morning blood draws for serum creatinine, calcium, phosphorus, 25-hydroxyvitamin D, 1,25D, iPTH, and FGF-23 levels. During the admission, all stool was collected with date and time noted, frozen, and sent to the laboratory of Dr. KM Hill Gallant and stored at –20 °C before mineral analysis. Polyethelyne glycol (PEG, molecular weight 3350) was given at every meal (1 g/meal, total of 3 g/day) during the duration of the diet as a nonabsorbable fecal adherence marker. Phosphorus and calcium balance Urine was pooled in timed 24-hour collections, and aliquots were acidified with 1% (vol./vol.) concentrated HCl and frozen at –80 °C until analysis. Thawed samples were diluted with 2% nitric acid, then analyzed for calcium and phosphorus for mineral analysis by inductively coupled plasma-optical emission spectrometry (ICP-OES; Optima 4300DV; Perkin Elmer, Shelton, CT). Urine creatinine levels were measured with a colorimetric assay using a COBAS MIRA clinical analyzer (Roche Diagnostics, Indianapolis, IN). Thawed fecal samples were homogenized and acidified before analysis.13 Homogenized fecal slurry (2-3 g) was placed into ceramic crucibles, with 4 replicates for each fecal sample, and allowed to dry overnight in an oven at 60 °C. Composite diets were prepared for each of the study menus to directly measure mineral content. Diets were thoroughly homogenized using minimal amounts of weighed distilled-deionized water and freeze-dried. Lyophilized diet samples (0.5-1 g) were then placed in crucibles, with 4 replicates per diet sample. Fecal and diet samples were dry ashed in a muffle furnace (Thermolyne Sybron Type 30400; Dubuque, IA) held at 600 °C for 3 days and diluted with 2% nitric acid for calcium and phosphorus analysis using inductively coupled plasma optical emission spectrometry.20,21 Balance and net absorption were calculated as the average values (mg/d) obtained over the CTRC inpatient 48-hour admission. Phosphorus balance (mg/d) was calculated as phosphorus dietary intake (mg/d) minus urine and fecal excretion (mg/d). Absorption as a percent of intake (%) was calculated as net absorption (mg/d)/dietary intake of mineral (mg/d) × 100. Calcium balance measures were determined similarly. Additional biochemistries Fasting serum and urine were collected at the start of the outpatient equilibration period (Start of controlled diet) and the end of the 48-hour CTRC inpatient stay (Day 9) and stored at –80 °C until analyzed. Briefly, 25-hydroxyvitamin D and 1,25 D were measured by immunoaffinity purification and LC-MS/MS. Parathyroid hormone (PTH) was quantified by an automated sandwich immunoassay and detected with chemiluminescence. Intact fibroblast growth factor 23 (iFGF23) was measured using the Kainos Human FGF-23 ELISA Kit, a 2-site enzyme-linked immunosorbent assay. Serum and urine calcium, phosphorus, and creatinine levels were measured by colorimetric assay using a COBAS MIRA clinical analyzer (Roche Diagnostics). The estimated glomerular filtration rate was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.22 Statistical analysis Participant characteristics at the start of the controlled diet were summarized using means and standard deviations, medians and interquartile ranges, or frequencies and proportions, as appropriate by group. Differences between groups were assessed using t tests, Fisher exact test, Wilcoxon rank sum tests, or chi-squared tests. A Wilcoxon Signed Rank Test (paired t test nonparametric equivalent) was used to test differences in means between the lanthanum carbonate and placebo groups for calcium and phosphorus balance measures. These data are presented as mean ± standard error of the mean (SEM) unless otherwise noted. For markers of CKD-MBD measured from the start of the controlled diet and at day 9, a repeated measures analysis with the mixed-effect models was performed, and an unstructured error covariance matrix was assumed. The model included the study group, time, and their interaction effect. Based on this model, the pre-post change within a group was tested, and the pre–post change was compared between the lanthanum carbonate and placebo treatment groups. The P value for the linear mixed model analysis represents the treatment × time effect, and time was modeled as a continuous variable. Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC). The significance level was set at ɑ = 0.05. Results Enrollment and baseline characteristics A total of fifteen subjects who completed the primary randomized controlled trial testing the effects of lanthanum carbonate versus placebo on vascular function were enrolled in this study and continued in their original randomized arm. None of the 15 subjects who were included in the balance extension phase withdrew from the study. However, one subject in the lanthanum carbonate group who completed the study was dropped from the phosphorus balance analysis because of insufficient stool samples, resulting in N = 6 for lanthanum carbonate and N = 8 for placebo. Table 1 shows the baseline characteristics of the 15 subjects who were included in the balance extension phase. The groups were similar at the initiation of the balance extension phase for age, sex, race, kidney function, and systolic and diastolic blood pressure.Table 1Baseline Characteristics at the Beginning of the Controlled Feeding StudyaVariableLanthanumN = 7PlaceboN = 8Age, y65 ± 664 ± 9Sex, male5 (71%)8 (100%)Race, White6 (86%)7 (88%)Diabetes4 (57%)6 (75%)Cardiovascular disease3 (43%)3 (38%)Smoking status Never2 (29%)4 (50%) Former5 (71%)4 (50%)Antihypertensive use7 (100%)8 (100%)Statin use4 (57%)7 (88%)BMI, kg/m233 ± 533 ± 5SBP, mm Hg119 ± 14128 ± 19DBP, mm Hg66 ± 473 ± 11eGFR (CKD-EPI), mL/min/1.73 m231 ± 835 ± 5Urinary protein, g protein/g creatinine1.00 [0.20-1.72]0.46 [0.12-1.32]Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.aValues presented as N (%), mean ± standard deviation, median [interquartile range]. Table 1Baseline Characteristics at the Beginning of the Controlled Feeding StudyaVariableLanthanumN = 7PlaceboN = 8Age, y65 ± 664 ± 9Sex, male5 (71%)8 (100%)Race, White6 (86%)7 (88%)Diabetes4 (57%)6 (75%)Cardiovascular disease3 (43%)3 (38%)Smoking status Never2 (29%)4 (50%) Former5 (71%)4 (50%)Antihypertensive use7 (100%)8 (100%)Statin use4 (57%)7 (88%)BMI, kg/m233 ± 533 ± 5SBP, mm Hg119 ± 14128 ± 19DBP, mm Hg66 ± 473 ± 11eGFR (CKD-EPI), mL/min/1.73 m231 ± 835 ± 5Urinary protein, g protein/g creatinine1.00 [0.20-1.72]0.46 [0.12-1.32]Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.aValues presented as N (%), mean ± standard deviation, median [interquartile range]. Baseline Characteristics at the Beginning of the Controlled Feeding Studya Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure. Values presented as N (%), mean ± standard deviation, median [interquartile range]. Adherence All subjects did well with adherence as they ate the prepared study food. As measured by chemical analysis of food leftovers, subjects consumed >95% of the prescribed dietary calcium and phosphorus. Phosphorus and calcium intake in the balance calculations were adjusted for calcium and phosphorus in leftover foods. Measured phosphorus intakes were 1007 ± 33 mg/d and 1093 ± 31 mg/d (mean ± SEM) for the lanthanum and placebo groups, respectively (Fig 2), and calcium intakes were 713 ± 29 mg/d and 768 ± 28 mg/d (mean ± SEM), respectively (Fig 3). Adherence for lanthanum carbonate and placebo was 100% for all participants as assessed by pill count.Figure 2Phosphorus balance in stage 3b and 4 CKD patients with and without lanthanum carbonate. Data are presented as mean ± SEM.Figure 3Calcium balance in stage 3b and 4 CKD patients with and without lanthanum carbonate. Data are presented as mean ± SEM. Phosphorus balance in stage 3b and 4 CKD patients with and without lanthanum carbonate. Data are presented as mean ± SEM. Calcium balance in stage 3b and 4 CKD patients with and without lanthanum carbonate. Data are presented as mean ± SEM. Phosphorus balance Phosphorus balance was different between lanthanum carbonate and placebo (–131 ± 163 vs 320 ± 141 mg/d, P = 0.05; Fig 2). There were differences between lanthanum carbonate and placebo for fecal phosphorus (775 ± 162 vs 259 ± 141 mg/d, P = 0.03), net intestinal phosphorus absorption (259 ± 159 vs 834 ± 138 mg/d, P = 0.01), and percent phosphorus absorption (26 ± 14% vs 76 ± 13%, P = 0.02). Urine phosphorus excretion was numerically lower with lanthanum carbonate compared with placebo, but this was not statistically significant (388 ± 60 vs 513 ± 56 mg/d, P = 0.15; Fig 2). Calcium balance Calcium balance was significantly lower with lanthanum carbonate compared with placebo (–46 ± 115 vs 410 ± 100 mg/d, respectively, P = 0.01; Fig 3); however, urine calcium excretion was not different between lanthanum carbonate and placebo (46 ± 11 vs 40 ± 11 mg/d, P = 0.73; Fig 3). There were significant differences between lanthanum carbonate and placebo for fecal calcium (737 ± 125 vs 317 ± 108 mg/d, P = 0.02), net intestinal calcium absorption (4 ± 114 vs 450 ± 99 mg/d, P = 0.01), and percent calcium absorption (3 ± 15% vs 59 ± 13%, P = 0.01). Fasting biochemistries, kidney function, and mineral handling We measured serum calcium, phosphorus, 25(OH)D, 1,25D, iPTH, and intact FGF23 levels at the start of the outpatient equilibration period (beginning of the controlled diet) and the end of the 48-hour inpatient stay (day 9). Mineral metabolism markers were similar at baseline between groups. The change in serum calcium was significantly lower in the lanthanum carbonate group than in the placebo group; however, overall, treatment with lanthanum carbonate did not affect the change in any of the circulating markers of mineral metabolism when compared with the placebo group (Table 2).Table 2Changes in Circulating Markers of CKD-MBDCirculating MarkerLanthanumN = 7P ValueaPlaceboN = 8P ValueaP Value Between groupsStart of Controlled Diet (Start of Extension Period)End of Control Diet (CTRC Stay)Start of Controlled Diet (Start of Extension Period)End of Control Diet (CTRC Stay)Serum calcium, mg/dL9.4 ± 0.69.3 ± 0.50.109.4 ± 0.69.8 ± 0.80.140.03Serum phosphorus, mg/dL3.5 ± 0.73.4 ± 0.70.873.5 ± 0.53.6 ± 0.40.590.6125 (OH)D43 ± 1047 ± 120.1448 ± 2453 ± 250.260.781,25 (OH)2D43 ± 2642 ± 180.8632 ± 931 ± 70.810.97iPTH (median IQR)73 [36-191]60 (41-194)0.7370 (44-118)83 (44-133)0.440.77FGF-23 (median IQR)103 (61, 119)77 (55, 112)0.31114 (82-129)159 (87-206)0.350.18Abbreviations: 25(OH)D, 25-hydroxyvitamin D; 1,25 (OH)2D, 1,25 dihydroxyvitamin D; FGF23, fibroblast growth factor 23.aP value testing for the difference in the change from the start of the controlled diet to day 9 in circulating markers of CKD-MBD between groups. Table 2Changes in Circulating Markers of CKD-MBDCirculating MarkerLanthanumN = 7P ValueaPlaceboN = 8P ValueaP Value Between groupsStart of Controlled Diet (Start of Extension Period)End of Control Diet (CTRC Stay)Start of Controlled Diet (Start of Extension Period)End of Control Diet (CTRC Stay)Serum calcium, mg/dL9.4 ± 0.69.3 ± 0.50.109.4 ± 0.69.8 ± 0.80.140.03Serum phosphorus, mg/dL3.5 ± 0.73.4 ± 0.70.873.5 ± 0.53.6 ± 0.40.590.6125 (OH)D43 ± 1047 ± 120.1448 ± 2453 ± 250.260.781,25 (OH)2D43 ± 2642 ± 180.8632 ± 931 ± 70.810.97iPTH (median IQR)73 [36-191]60 (41-194)0.7370 (44-118)83 (44-133)0.440.77FGF-23 (median IQR)103 (61, 119)77 (55, 112)0.31114 (82-129)159 (87-206)0.350.18Abbreviations: 25(OH)D, 25-hydroxyvitamin D; 1,25 (OH)2D, 1,25 dihydroxyvitamin D; FGF23, fibroblast growth factor 23.aP value testing for the difference in the change from the start of the controlled diet to day 9 in circulating markers of CKD-MBD between groups. Changes in Circulating Markers of CKD-MBD Abbreviations: 25(OH)D, 25-hydroxyvitamin D; 1,25 (OH)2D, 1,25 dihydroxyvitamin D; FGF23, fibroblast growth factor 23. P value testing for the difference in the change from the start of the controlled diet to day 9 in circulating markers of CKD-MBD between groups. Discussion Among individuals with CKD 3b-4 and normophosphatemia, lanthanum carbonate had a lower whole body phosphorus balance on a controlled daily intake of 1,000 mg/d phosphorus compared with placebo. There was significantly higher fecal phosphorus excretion and a trend for lower urine excretion of phosphorus in those taking lanthanum carbonate. The lower urinary phosphorus excretion is likely secondary to the significantly lower phosphorus absorption (net and %), which is also reflected in the higher fecal phosphorus excretion. Lanthanum carbonate produced a lower calcium balance compared with placebo while participants were consuming a diet containing approximately 750 mg of calcium daily. The lower calcium balance was primarily driven by lower intestinal calcium absorption, as evidenced by the higher stool calcium excretion and lower intestinal calcium absorption (net and %) from balance data. Notably, this apparent difference in calcium absorption was not reflected in urinary calcium excretion, which was low and did not differ between lanthanum carbonate and placebo. This agrees with previously reported findings that 24-hour urine calcium excretion in nondialysis-requiring CKD subjects is low and not reflective of intestinal calcium absorption.12,13 It has been previously suggested that intestinal calcium absorption could be impaired in early stages of kidney disease based on low urinary calcium excretion observed in patients with CKD.23 However, previous calcium balance and kinetic studies have demonstrated that intestinal calcium absorption is low in nondialysis-requiring CKD patients when they ingest normal or low quantities of calcium, which may be viewed as a failure of adaptation to variations in calcium intake.12,13 It is well established that this process of intestinal adaptation in CKD requires adequate intake and normal metabolism of calciferol. Reduced conversion of calciferol to 1,25D could account, at least in part, for the decreased calcium absorption observed in nondialysis-requiring CKD patients ingesting low calcium diets.24 However, in this study, the CKD patients randomized to the control arm had a higher net calcium absorption when compared with previous published balance studies.12,13 These findings can be explained by the higher 1,25D circulating levels measured in the CKD patients included in this study when compared with previous reports.12,13 Our results provide evidence that the overall effect of lanthanum carbonate in stages 3b and 4 CKD is to produce a negative phosphorus and calcium balance, which is associated with lower intestinal absorption and higher fecal phosphorus and calcium excretion. Phosphorus retention is an established risk factor for decreased vascular health5, increased vascular calcifications3, 4, 5, and increased cardiovascular morbidity and mortality. However, very few phosphorus balance studies have been performed.14 Although it is assumed that patients with advanced CKD have phosphorus retention, as there is an increased demand to excrete the average dietary phosphorus load, previous balance studies have demonstrated that stage 3 and 4 CKD patients remain in neutral phosphorus balance when given a calcium-based phosphate binder.13 The design of our study is different from previously published balance studies; however, we demonstrated that advanced CKD patients are in positive phosphorus balance despite being normophosphatemic, and phosphorus balance can be improved with the administration of lanthanum carbonate. The administration of lanthanum carbonate did not cause any significant changes in serum phosphorus, despite the observed lower urine phosphorus excretion. In addition, we did not observe changes in 1,25D, iPTH, and iFGF-23, indicating that although there was a change in phosphorus balance, it did not elicit changes in the phosphorus regulatory hormones, likely related to the small sample size. The 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD discourages the prescription of phosphate-lowering therapies in individuals with nondialysis-requiring CKD and normal serum phosphorus levels.25 This recommendation is mainly based in that there is a lack of demonstrated efficacy of phosphate binders for lowering serum phosphate in nondialysis-requiring patients with CKD stage 3 and 4; the safety of phosphate binders in this population is unproven; and there is an absence of data showing that dietary phosphate restriction improves clinical outcomes. However, as shown in this study, patients with nondialysis-requiring CKD who have an intake of 1,000 mg of phosphorus are in positive phosphorus balance. Hence, the future guidelines should consider encouraging research in preventing, rather than treating, hyperphosphatemia in nondialysis-requiring CKD with targeted nutrition counseling, which can positively affect dietary phosphate intake without affecting overall nutrition. Limitations of the study include that dietary calcium and phosphorus intake were fixed by protocol and are not representative of each participant’s usual daily intake, the small sample size as balance studies are demanding to perform for the patient and investigative team, and the limited proportion of female participants (related to recruitment of older Veterans), potentially limiting the generalizability of the findings. In addition, the short inpatient study duration of 2 days is also a limitation for interpreting whole-body balance data, and particularly, fecal phosphorus data. With shorter balance periods, infrequent fecal samples can lead to artificially high balance (retention) values. Although 2-day balance studies have been successfully reported previously, we recognize that stool frequency is variable and can be sparse over 2 days. Hence, the short balance period and infrequent fecal samples are plausible explanations for our balance data showing phosphorus retention in nondialysis-requiring CKD patients. Longer-duration balance studies are needed to make more accurate conclusions on the absolute values of whole-body phosphorus balance. Furthermore, the balance study was performed at the end of a 12-week intervention with lanthanum carbonate; it likely does not represent the effects of chronic phosphate binder administration on mineral balance. This study is the first balance study in advanced CKD performed after 12 weeks of administration of a noncalcium-containing phosphate binder, lanthanum carbonate, that evaluates both calcium and phosphorus balance. Our findings contradict the findings of previous balance studies that phosphorus balance is neutral in CKD, and we show that phosphorus and calcium balance are lowered with the use of a non-calcium-based binder in advanced CKD. Whether negative phosphorus or calcium balance with lanthanum carbonate is associated with beneficial clinical outcomes in CKD warrants further investigation.